shadow_tr

Research

Tulane Diabetes Research Program


Franck Mauvais-Jarvis, MD, PhD

The mission of the Tulane Diabetes Research Program is to provide a collaborative research community and infrastructure to Tulane research investigators studying the molecular bases and therapeutic avenues for diabetes mellitus, obesity and their complications.  

Franck Mauvais-Jarvis, MD, PhD, Director of the Tulane Diabetes Research Program, Price-Goldsmith Professor of Nutrition


lab

A variety of research resources are available in the Section of Endocrinology. A list of current studies is found below. These research projects and others through the Clinical Trials Cooperative provide numerous opportunities for research and scholarly publication, and are an integral part of the Endocrinology department. Publications relating to this research are found on our publications page. For more publications, please reference specific faculty or fellow pages.


Current Studies



ABPM

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure:  A Pilot Study



    • Sponsor: Investigator-Initiated

    • Principal Investigator: Dr. Tina Thethi

    • Study dates: 04/18/2014 - ongoing



GRADE

Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study



Mesoblast

Protocol #MSB-DM003 - "A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients with Type 2 Diabetes Sub...

Endobarrier

Protocol #09-1 – “A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier® Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Metformin and/or SU Ant

SUSTAIN

Protocol #NN9535-3744 - SUSTAIN™ 6 - Long term outcomes - "A long-term, randomized, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 ...


  • Sponsor: GI Dynamics, Inc.

  • Principal Investigator: Dr. Vivian Fonseca

  • Study dates: 02/13-ongoing

  • Study website: www.endobarriertrial.com



Prt#ITCA 650-CLP-103

Protocol #ITCA 650-CLP-103 - “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes”


  • Sponsor: Novo Nordisk

  • Principal Investigator: Dr. Tina Thethi

  • Study dates: 06/13-ongoing



Prt#ITCA 650-CLP-107

Protocol #ITCA 650-CLP-107 – “A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes”


  • Sponsor: Intarcia Therapeutics, Inc.

  • Principal Investigator: Dr. Tina Thethi

  • Study dates: 07/13-ongoing



ACCORDION

CCORDION: Action to Control Cardiovascular Risk in Diabetes Follow On


  • Sponsor: Intarcia Therapeutics, Inc.

  • Principal Investigator: Dr. Tina Thethi

  • Study dates: 07/13-ongoing



LEADER

Protocol #EX2211-3748 - LEADER: "Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A long-term, multi centre, international, randomized double-blind, placebo-controlled trial to determine liraglutide effects on ...


  • Sponsor: NIH

  • Principal Investigator: Dr. Vivian Fonseca

  • Study Dates: 05/11-ongoing



1430 Tulane Ave, New Orleans, LA 70112 504-988-5263 medsch@tulane.edu